Meeting
2018 ASCO Annual Meeting
Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
Authors
Ramesh Rengan
Department of Radiation Oncology, University of Washington, Seattle, WA
Ramesh Rengan , Rosemarie Mick , Daniel Pryma , Lilie L. Lin , John Paul Christodouleas , John Peter Plastaras , Charles B. Simone II, Anjali K. Gupta , Tracey L. Evans , James Stevenson , Corey J. Langer , John Kucharczuk , Joseph S. Friedberg , Sarah Lam , Dana Patsch , Stephen M. Hahn , Amit Maity
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00589056
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8552)
DOI
10.1200/JCO.2018.36.15_suppl.8552
Abstract #
8552
Poster Bd #
158
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.
First Author: Vanita Noronha
Poster
2022 ASCO Annual Meeting
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
First Author: Greg Andrew Durm
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2020 ASCO Virtual Scientific Program
Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study.
First Author: Margitta Retz